Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

This trial is testing a combination of two cancer drugs — a liposomal chemotherapy (CPX-351, a special version of daunorubicin and cytarabine packaged for better delivery) and venetoclax (a targeted drug that helps cancer cells self-destruct) — for people with acute myeloid leukemia (AML), a type of blood cancer. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with acute myeloid leukemia (AML) - For the relapsed/refractory group (cohort A): your AML has come back or stopped responding to prior treatment - For the newly diagnosed group (cohort B): you are 18–69 years old and have received no prior AML treatment **You may NOT be eligible if...** - You have a serious active infection - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding - You have a leukemia type that requires a different treatment approach (like APL) Talk to your doctor to see if this trial is right for you.